Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06774079 · ClinicalTrials.gov registry record · Phase 4
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
A Phase 4 study of Crohn Disease, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06774079: Recruiting Phase 4 study of Crohn Disease, sponsored by University of Miami.
NCT06774079 is a Phase 4 study of Crohn Disease that is actively recruiting participants, run by University of Miami. The registered enrollment target is 24 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06774079, a Phase 4 study of Crohn Disease, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) for Crohn's disease patients with mild disease who are on stable doses of biologic medication (infliximab or adalimumab) and who have a body mass index (BMI) of at least 27.
Primary Outcome
The percentage of participants retained will be measured
Conditions Studied
Interventions
- DRUG Tirzepatide
- BEHAVIORAL Mediterranean diet
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2026-03-05 |
| Phase | Phase 4 |
What NCT06774079 shows while recruiting
NCT06774079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06774079 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06774079 about?
NCT06774079 is a clinical study titled "Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients". The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) f...
What is the current status of trial NCT06774079?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2025-03-05. Estimated completion is 2026-03-05.
What conditions does trial NCT06774079 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT06774079?
The interventions under investigation include: Tirzepatide (DRUG), Mediterranean diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT06774079?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06774079 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06774079's enrollment target sits among peer trials
24 59th of 71 higher than 13 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
RECRUITING · Phase 4
-
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
RECRUITING · Phase 4
-
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
ACTIVE NOT RECRUITING · Phase 4
-
Triple Combination Therapy in High Risk Crohn's Disease (CD)
COMPLETED · Phase 4
-
Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
COMPLETED · Phase 4
-
Flagyl Microbiome in Crohn's Disease
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI